药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Pergolide
Caplacizumab
The risk or severity of bleeding can be increased when Caplacizumab is combined with Bosutinib.
Pergolide
Andrographolide
The risk or severity of bleeding can be increased when Andrographolide is combined with Bosutinib.
Pergolide
Ibudilast
The risk or severity of bleeding can be increased when Ibudilast is combined with Bosutinib.
Pergolide
Defibrotide
The risk or severity of bleeding can be increased when Defibrotide is combined with Bosutinib.
Pergolide
Epoprostenol
The risk or severity of bleeding can be increased when Epoprostenol is combined with Bosutinib.
Pergolide
Ridogrel
The risk or severity of bleeding can be increased when Ridogrel is combined with Bosutinib.
Pergolide
Moderna COVID-19 Vaccine
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Bosutinib.
Pergolide
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bosutinib.
Pergolide
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bosutinib.
Pergolide
Varicella Zoster Vaccine (Recombinant)
The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Bosutinib.
Pergolide
Yersinia pestis 195/p antigen (formaldehyde inactivated)
The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib.
Pergolide
Pertussis vaccine
The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bosutinib.
Pergolide
Smallpox (Vaccinia) Vaccine, Live
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bosutinib.
Pergolide
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bosutinib.
Pergolide
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Bosutinib.
Pergolide
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Bosutinib.
Pergolide
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib.
Pergolide
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Bosutinib.
Pergolide
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib.
Pergolide
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib.